Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Debt
Short-term and long-term borrowings combined.
Citius Oncology, Inc.NASDAQ: CTOR
Total Debt · Q2 FY2026 · quarter ended Mar 2026
Total debt broadly unchanged from a year ago
Total debt stood at $3.8M at the end of Q2 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.
Context
- Total debt amounted to 3.8% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 3.8M USD
- Year-over-year change
- +0.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 3.8M | +0.0% |
| FY2024 | 2024-09-30 | 3.8M | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Total Debt vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total debt of $3.8M is the 5th highest of the 10 companies compared; the peer median is $2.94M.
- Its year-over-year change of +0.0% is the 4th highest of 8, against a peer median of -7.9%.
- Total debt amounts to 3.8% of total assets for CTOR, versus a peer median of 4.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $106.36M | +156.2% | +354.7% | 36.2% | |
| Mar 2026 | $80.5M | -10.1% | -20.1% | 68.4% | |
| Mar 2026 | $76.79M | -7.9% | -10.7% | 27.0% | |
| Mar 2026 | $18.77M | +35.0% | -10.7% | 21.6% | |
CTORCitius Oncology, Inc. | Mar 2026 | $3.8M | +0.0% | — | 3.8% |
| Mar 2026 | $2.94M | -90.5% | -57.4% | 0.6% | |
| Mar 2026 | $2.57M | +4.1% | -0.8% | 3.9% | |
| Mar 2026 | $2.47M | -37.5% | -24.2% | 4.2% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K | — | +0.0% | 4.5% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CTOR) | $2.94M | -7.9% | -10.7% | 4.5% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.